Form 8-K

0001171843-22-005343.txt : 20220804 0001171843-22-005343.hdr.sgml : 20220804 20220804073216 ACCESSION NUMBER: 0001171843-22-005343 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220804 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220804 DATE AS OF CHANGE: 20220804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 221134712 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 8-K 1 f8k_080322.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 4, 2022

_______________________________

Arbutus Biopharma Corporation

(Exact name of registrant as specified in its charter)

_______________________________

British Columbia, Canada	001-34949	98-0597776
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

701 Veterans Circle

Warminster, Pennsylvania 18974

(Address of Principal Executive Offices) (Zip Code)

(267) 469-0914

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, without par value	ABUS	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 4, 2022, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2022 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description

99.1		Press release dated August 4, 2022
104		Cover page interactive data file (formatted as inline XBRL).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Arbutus Biopharma Corporation


Date: August 4, 2022	By:	/s/ David C. Hastings
		David C. Hastings
		Chief Financial Officer

EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track

Financially strong with a projected cash runway into the second quarter of 2024

Conference Call and Webcast Today at 8:45 AM ET

WARMINSTER, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its second quarter 2022 financial results and provides corporate updates.

“This quarter we presented data at the EASL ILC which highlighted the advancements we have made in developing our lead RNAi therapeutic AB-729, capsid inhibitor AB-836, and PD-L1 inhibitor AB-101 to potentially provide a functional cure for patients with chronic hepatitis B virus (cHBV). For AB-729 we presented exciting data showing achievement of virologic control in five cHBV patients after discontinuing treatment with AB-729 and nucleos(t)ide analog (NA)-therapy. We continue to follow these patients, as well as others that have elected to discontinue treatment, and look forward to providing additional follow-up data later this year,” said William Collier, Arbutus’ President and Chief Executive Officer. “In addition, we were impressed with the competitive and robust antiviral activity seen with AB-836 and we plan to initiate a Phase 1 study in healthy volunteers to better characterize the unexpected ALT increases seen in some patients. We also look forward to completing IND-enabling studies this year with AB-161, our RNAi destabilizer, and AB-101.”

Mr. Collier continued, “We are continuing to advance our development efforts with our nsp5 main protease (M^pro) and nsp12 viral polymerase programs for SARS-CoV-2 and future coronavirus outbreaks. Finally, our financial position is strong with a projected cash runway into the second quarter of 2024.”

Pipeline Updates:
AB-729 (RNAi Therapeutic)

Arbutus presented new on-treatment data as well as long-term off-treatment data for cHBV patients in the AB-729-001 clinical trial at the 2022 European Association for the Study of the Liver (EASL) International Liver Congress™ (ILC) on June 25^th. Key findings included:
- AB-729 provided robust and comparable HBsAg declines regardless of dose, dosing interval or baseline characteristics
- 50% of patients (16 out of 32) maintained HBsAg levels below 100 IU/mL 24 weeks after their last dose of AB-729
- There was no evidence of virologic or clinical relapse in 8-24 weeks of follow-up in the first five patients who discontinued both AB-729 and NA therapy
- AB-729 continues to restore HBV-specific T-cells and decrease exhausted T-cells
- AB-729 remains generally safe and well-tolerated after completing dosing in 41 patients

Dosed first patient in the AB-729-202 Phase 2a clinical trial evaluating AB-729, in combination with VTP-300, Vaccitech plc’s (Vaccitech) therapeutic vaccine and nucleos(t)ide analogue therapy (NA), in cHBV patients.
Enrollment is continuing in the Phase 2a clinical trial evaluating AB-729 in combination with ongoing NA therapy and short courses of Peg-IFNα-2a (AB-729-201) in cHBV patients. The Company is on-track to report initial data in the second half of 2022.
Dosing is continuing in the Phase 2a clinical trial evaluating AB-729 in combination with vebicorvir (VBR), Assembly Biosciences, Inc.’s HBV core inhibitor (capsid inhibitor), and an NA in cHBV patients. Preliminary data are expected in the second half of 2022.

AB-836 (Oral Capsid Inhibitor)

In June 2022 Arbutus presented data at EASL from its AB-836-001 Phase 1a/1b clinical trial in which the Company is evaluating the safety and tolerability of multiple doses of AB-836 in patients with cHBV infection. AB-836 dosed at 100mg or 200mg once daily for 28 days achieved mean declines in HBV DNA of 3.04 and 3.55 log₁₀ IU/mL, respectively. Two HBeAg+ patients in the 100mg dose cohort had transient Grade 3 ALT elevations that resolved with continued dosing and were not considered treatment emergent adverse events (TEAEs). Two patients in the 200mg cohort had Grade 3 and Grade 4 ALT elevations on the last day of dosing (Day 28) that returned to baseline during follow up which were reported as TEAEs. Based on these ALT findings, the Company plans to conduct an additional Phase 1 trial in healthy volunteers to determine whether or not these ALT elevations are beneficial or could be the result of liver toxicity. The Company will provide an update with respect to the status and timing of this clinical trial in the second half of 2022.

AB-101 (Oral PD-L1 Inhibitor)

In June 2022 Arbutus presented data at EASL showing that once daily oral administration of AB-101 resulted in T-cell activation in a preclinical model. In addition, AB-101 activates and reinvigorates HBV-specific T-cells in vitro. The company is on-track to complete IND-enabling studies for AB-101 in the second half of 2022.

AB-161 (Oral RNA Destabilizer)

Arbutus is conducting IND-enabling studies for AB-161, its oral RNA destabilizer. The Company intends to complete IND-enabling studies for AB-161 in the second half of 2022.

COVID-19 and Pan-Coronavirus Programs

We see an opportunity to pursue a combination therapy consisting of compounds that inhibit the SARS-CoV-2 nsp5 main protease and nsp12 viral polymerase, to achieve better patient treatment outcomes and use in prophylactic settings.
Arbutus plans to nominate a lead candidate that inhibits the SARS-CoV-2 nsp5 main protease (M^pro) in the second half of 2022 and then advance that compound into IND-enabling studies.
The Company is continuing lead optimization activities for an nsp12 viral polymerase candidate.

PD-L1 in Oncology

Preclinical data was selected for publication at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2022 showing that Arbutus’ oral small-molecule PD-L1 inhibitors in development, which possess a novel mechanism of action, have the ability to mediate T-cell activation in primary human immune cells. The anti-tumor efficacy seen in vivo was comparable to anti-PD-L1 antibodies. The data was published in the Journal of Clinical Oncology.

Financial Results

Cash, Cash Equivalents and Investments

As of June 30, 2022, the Company had cash, cash equivalents and investments in marketable securities of $200.6 million, as compared to $191.0 million as of December 31, 2021.

During the six months ended June 30, 2022, the Company received a $40.0 million (net of withholding taxes) upfront payment from Qilu Pharmaceutical Co., Ltd. (“Qilu”) related to a technology transfer and license agreement for AB-729 in greater China, $15.0 million of gross proceeds from Qilu’s equity investment in the Company and $0.3 million of net proceeds from the issuance of common shares under Arbutus’s “at-the-market” offering program. These cash inflows were partially offset by $43.7 million of cash used in operations. The Company expects a net cash burn between $90 to $95 million in 2022, not including the $55 million of proceeds received from Qilu, and believes its cash runway will be sufficient to fund operations into the second quarter of 2024.

Revenue

Revenues were $14.2 million for the three months ended June 30, 2022 compared to $2.3 million for the same period in 2021. The increase of $11.9 million was due primarily to $11.0 million of revenue recognition from the Company’s license agreement with Qilu based on employee labor hours expended by the Company during the three months ended June 30, 2022 to perform its manufacturing obligations under the license agreement.

Operating Expenses

Research and development expenses were $22.9 million for the three months ended June 30, 2022, compared to $15.8 million for the same period in 2021. The increase of $7.1 million was due primarily to an increase in expenses related to the Company’s multiple, ongoing AB-729 Phase 2a clinical trials, including its collaborations with Assembly and Vaccitech, and an increase in expenses for its early-stage development programs, including AB-101 and AB-161. General and administrative expenses were $5.2 million for the three months ended June 30, 2022, compared to $4.5 million for the same period in 2021. This increase was due primarily to increases in employee compensation and non-cash stock-based compensation expense.

Net Loss

For the three months ended June 30, 2022, the Company’s net loss attributable to common shares was $14.2 million, or a loss of $0.10 per basic and diluted common share, as compared to a net loss attributable to common shares of $22.7 million, or a loss of $0.23 per basic and diluted common share, for the three months ended June 30, 2021. Net loss attributable to common shares for the three months ended June 30, 2021 included $3.3 million of non-cash expense for the accrual coupon on the Company’s convertible preferred shares, which converted into 22.8 million common shares in October 2021.

Outstanding Shares

As of June 30, 2022, the Company had approximately 148.8 million common shares issued and outstanding, as well as approximately 15.9 million stock options outstanding. Roivant Sciences Ltd. owned approximately 26% of the Company’s outstanding common shares as of June 30, 2022.

COVID-19 Impact

The COVID-19 pandemic has resulted in and will likely continue to result in significant disruptions to businesses. Measures implemented around the world in attempts to slow the spread of COVID-19 have had, and will likely continue to have, a major impact on clinical development, at least in the near-term, including shortages and delays in the supply chain and prohibitions in certain countries on enrolling subjects and patients in new clinical trials. While the Company has been able to progress with its clinical and pre-clinical activities to date, it is not possible to predict if the COVID-19 pandemic will materially impact the Company’s plans and timelines in the future.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF LOSS
(in thousands, except share and per share data)

	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2022				2021
Revenue
Collaborations and licenses	$	12,556		$	1,185		$		23,774		$		2,339
Non-cash royalty revenue	1,685			1,144				3,048				2,103
Total Revenue	14,241			2,329				26,822				4,442
Operating expenses
Research and development	22,942			15,799				41,404				29,581
General and administrative	5,200			4,478				10,092				8,356
Change in fair value of contingent consideration	208			694				409				823
Total operating expenses	28,350			20,971				51,905				38,760
Loss from operations	(14,109		)	(18,642		)		(25,083		)		(34,318		)
Other income (loss)
Interest income	396			31				555				70
Interest expense	(482		)	(763		)		(988		)		(1,535		)
Foreign exchange (losses) gains	3			(13		)		3				15
Total other loss	(83		)	(745		)		(430		)		(1,450		)
Net loss before income tax expense	(14,192		)	(19,387		)		(25,513		)		(35,768		)
Income tax expense	-			-					(4,444	)			-
Net loss	(14,192		)	(19,387		)			(29,957	)			(35,768	)
Dividend accretion of convertible preferred shares	-			(3,266		)			-				(6,478	)
Net loss attributable to common shares	$	(14,192	)	$	(22,653	)	$	(29,957		)	$	(42,246		)
Loss per share
Basic and diluted	$	(0.10	)	$	(0.23	)	$		(0.20	)	$		(0.44	)
Weighted average number of common shares
Basic and diluted	148,750,048			96,869,805				148,589,711				95,153,545

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)

	June 30, 2022		December 31, 2021
Cash, cash equivalents and marketable securities, current	$	150,199	$	155,317
Accounts receivable and other current assets	7,592		5,344
Total current assets	157,791		160,661
Property and equipment, net of accumulated depreciation	5,493		5,983
Investments in marketable securities, non-current	50,450		35,688
Right of use asset	1,922		2,092
Other non-current assets	180		61
Total assets	$	215,836	$	204,485
Accounts payable and accrued liabilities	$	12,474	$	10,838
Deferred revenue	16,973		-
Lease liability, current	377		383
Total current liabilities	29,824		11,221
Liability related to sale of future royalties	14,233		16,296
Deferred revenue, non-current	10,842		-
Contingent consideration	5,707		5,298
Lease liability, non-current	2,088		2,231
Total stockholders’ equity	153,142		169,439
Total liabilities and stockholders’ equity	$	215,836	$	204,485

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW
(in thousands)

	Six Months Ended June 30,
	2022			2021
Net loss	$	(29,957	)	$	(35,768	)
Non-cash items	3,154			5,005
Change in deferred license revenue	27,815			-
Other changes in working capital	(686		)	(1,127		)
Net cash provided by (used in) operating activities	326			(31,890		)
Net cash used in investing activities	(73,886		)	(20,526		)
Issuance of common shares pursuant to Share Purchase Agreement	10,973			-
Cash provided by other financing activities	625			31,163
Net cash provided by financing activities	11,598			31,163
Effect of foreign exchange rate changes on cash and cash equivalents	-			(44		)
Decrease in cash and cash equivalents	(61,962		)	(21,297		)
Cash and cash equivalents, beginning of period	109,282			52,251
Cash and cash equivalents, end of period	47,320			30,954
Investments in marketable securities	153,329			90,331
Cash, cash equivalents and marketable securities, end of period	$	200,649		$	121,285

Conference Call and Webcast Today

Arbutus will hold a conference call and webcast today, Thursday, August 4, 2022, at 8:45 AM Eastern Time to provide a corporate update. You can access a live webcast of the call through the Investors section of Arbutus’ website at www.arbutusbio.com. Alternatively, you can dial (800) 715-9871 or (646) 307-1963 and reference conference ID: 5109143.

An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling (800) 770-2030 or (609) 800-9909, and reference conference ID: 5109143

About AB-729

AB-729 is an RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral proteins and antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus. AB-729 targets hepatocytes using Arbutus’ novel covalently conjugated N-Acetylgalactosamine (GalNAc) delivery technology that enables subcutaneous delivery. Clinical data generated thus far has shown single- and multi-doses of AB-729 to be generally safe and well-tolerated while providing meaningful reductions in hepatitis B surface antigen and hepatitis B DNA. AB-729 is currently in multiple Phase 2a clinical trials.

About AB-836

AB-836 is a next generation oral hepatitis B virus (HBV) capsid inhibitor that interacts with HBV core protein, which in turn is required for viral replication. The current standard-of-care therapy for HBV is primarily nucleos(t)ide analogues that inhibit the viral polymerase and significantly reduce, but do not eliminate viral replication. AB-836 in combination with nucleos(t)ide analogues is designed to completely eliminate viral replication in infected cells by preventing the assembly of functional viral capsids. In addition, AB-836 has been shown to inhibit the replenishment of covalently closed circular DNA (cccDNA), the viral genetic reservoir which the virus needs to replicate itself.

About AB-101

Immune checkpoints such as PD-1/PD-L1 play an important role in the induction and maintenance of immune tolerance and in T-cell activation. We have identified a class of small molecule oral PD-L1 inhibitors that we believe will allow for controlled checkpoint blockade, enable oral dosing, and mitigate systemic safety issues typically seen with checkpoint antibody therapies. Our lead oral PD-L1 inhibitor candidate, AB-101, is currently in IND-enabling studies. We believe AB-101 has the potential to be used in combination with other approved and investigational agents for our mission to achieve a functional cure for HBV chronically infected patients. We are also exploring oncology applications for our internal PD-L1 portfolio.

About HBV

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). HBV can cause chronic infection which leads to a higher risk of death from cirrhosis and liver cancer. Chronic HBV infection represents a significant unmet medical need. The World Health Organization estimates that over 290 million people worldwide suffer from chronic HBV infection, while other estimates indicate that approximately 2.4 million people in the United States suffer from chronic HBV infection. Approximately 820,000 people die every year from complications related to chronic HBV infection despite the availability of effective vaccines and current treatment options.

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. In HBV, we are developing a RNAi therapeutic, an oral capsid inhibitor, an oral PD-L1 inhibitor, and an oral RNA destabilizer to potentially identify a combination regimen with the aim of providing a functional cure for patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening. It is currently being evaluated in multiple phase 2 clinical trials. We also have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including SARS-CoV-2). In addition, we are exploring oncology applications for our internal PD-L1 portfolio. For more information, visit www.arbutusbio.com.

Forward-Looking Statements and Information

This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward-looking information within the meaning of Canadian securities laws (collectively, forward-looking statements). Forward-looking statements in this press release include statements about our future development plans for our product candidates; the expected cost, timing and results of our clinical development plans and clinical trials with respect to our product candidates; our expectations with respect to the release of data from our clinical trials and the expected timing thereof; our expectations and goals for our collaborations with third parties and any potential benefits related thereto; the potential for our product candidates to achieve success in clinical trials; and our expected financial condition, including the anticipated duration of cash runways and timing regarding needs for additional capital.

With respect to the forward-looking statements contained in this press release, Arbutus has made numerous assumptions regarding, among other things: the effectiveness and timeliness of preclinical studies and clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the continued demand for Arbutus’ assets; and the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies, including uncertainties and contingencies related to the ongoing COVID-19 pandemic and patent litigation matters.

Additionally, there are known and unknown risk factors which could cause Arbutus’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: anticipated pre-clinical studies and clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested product candidate; Arbutus may elect to change its strategy regarding its product candidates and clinical development activities; Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus’ products; economic and market conditions may worsen; uncertainties associated with litigation generally and patent litigation specifically; Arbutus and its collaborators may never realize the expected benefits of the collaborations; market shifts may require a change in strategic focus; and the ongoing COVID-19 pandemic could significantly disrupt Arbutus’ clinical development programs.

A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus’ Annual Report on Form 10-K, Arbutus’ Quarterly Reports on Form 10-Q and Arbutus’ continuous and periodic disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

Contact Information

Investors and Media

William H. Collier
President and CEO
Phone: 267-469-0914
Email: ir@arbutusbio.com

Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com

EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Aug. 04, 2022
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Aug. 04, 2022
Entity File Number	001-34949
Entity Registrant Name	Arbutus Biopharma Corporation
Entity Central Index Key	0001447028
Entity Tax Identification Number	98-0597776
Entity Incorporation, State or Country Code	A1
Entity Address, Address Line One	701 Veterans Circle
Entity Address, City or Town	Warminster
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	18974
City Area Code	267
Local Phone Number	469-0914
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Shares, without par value
Trading Symbol	ABUS
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 8 f8k_080322_htm.xml IDEA: XBRL DOCUMENT 0001447028 2022-08-04 2022-08-04 iso4217:USD shares iso4217:USD shares 0001447028 false 8-K 2022-08-04 Arbutus Biopharma Corporation A1 001-34949 98-0597776 701 Veterans Circle Warminster PA 18974 267 469-0914 false false false false Common Shares, without par value ABUS NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( <\!%4'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " '/ 15V?20R>X K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)VE%)'1[43PI""XHWD(RNQML_I",M/OVMG&WB^@#>,S,+]]\ M ]/I*'5(^)Q"Q$06\]7D!I^ECAMV((H2(.L#.I7K.>'GYBXDIVA^ICU$I3_4 M'J'A_ 8GQI:Q;69]) M>8WSKVPE'2-NV'GR:WMWOWU@?<.;IN*W%;_>"B';1@KQOKC^\+L(NV#LSOYC MX[-@W\&ON^B_ %!+ P04 " '/ 15F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M <\!%57H>]E2 0 ( 0 8 >&PO=V]R:W-H965T&UL MG9C;;N,V$(9?A5"!H@7BZ&#%A]0VH#A)&^QNUHVS&Z!%+VB)MHB52)6DXN3M M.Y0=R9N51T9O8E'2_/HT'/U#9K*5ZIM.&3/D)<^$GCJI,<6EZ^HX93G5Y[)@ M JZLI<-W)QRX8Y5:]7 M+)/;J>,[;R<>^"8U]H0[FQ1TPY;,?"D6"D9NK9+PG G-I2"*K:=.Y%]>!:$- MJ.[XRME6'QP3^RHK*;_9P5TR=3Q+Q#(6&RM!X>>9S5F6627@^'_>@BO*:&CJ;*+DERMX-:O:@ M>M4J&N"XL+.R- JN$KU_S]3'UV;6,2ZA%0QY?"]8&AX>/>A\0B+"&"%&5" B2BN(VHYLV M"CQ^33/-$(Z+FN/BM&0LF.(R(3W+B&Y_F]?C@.QPC/L.89GL+SP#;H=ZY&.0!Q[OGP(9)0DXHSY[.R ?X3[R6;23 MX9)#SR=?F6%0TIK,N8HSS%G\I@_XJ(W_@#JW(TCDH]R*5DQ<[@D^%2ZT>5\I MW],U7<#'??P]73W/"R6?N8C;,XEK+B(,K>D-/F[N[]$64AOXD/_BQ?'BPQ7] MT7@88FQ-O_!QFZ\F,8)%XW$47" 8##&0ICGXN+-_E#'D9)%*@76'#I%P,.YY M8Q]-3=,>?-S7GQ0WA@E(3)Z78F]NNI4*%^IJ[G[3"7SRM>@Z!**K+TN,I#'Z M #?EMTR1FY1O876O]3X?9?U!+ P04 " '/ 15GZ ;\+$" #B# #0 M 'AL+W-T>6QEO%DN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZF MTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,7 M8&F? KP(&K XU7=>&18/ MQA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B< M45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^, M%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL> M]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PEY7>>9 ]IV03NA1.XJR MY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?#$T%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/ MAG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+ MV.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0 MIA@"IQ%', ; 4/2='@//GL?)=-[*CG_5U/\!%!+ P04 " '/ 15EXJ[ M', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6 M!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV M)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(= MI7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( M <\!%6JQ"(6,P$ "(" / >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5 M*A^P%K0A#5%>0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>]I31=B;FJ19IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y M&+6VG-X"$B@$*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C% MB/%*0:S;%4S.Y68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\ M@RX/J!5Z0B? :ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'! M=09#K+&))@G60VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV M4VPYZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04 " '/ 15)!Z; MHJT #X 0 &@ 'AL+U]R96QS+W=O[IFB MG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6 M<%H@XLD@;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% @ !SP$ M5660>9(9 0 SP, !, !;0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O M$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1 ML.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3K MU3.T.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY8 M4(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F," MJ;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R M]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]> M?P%02P$"% ,4 " '/ 15!T%-8H$ "Q $ @ $ M 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( <\!%79])#)[@ "L" M 1 " :\ !D;V-0&UL4$L! A0#% @ !SP$55>A[V5(! @! !@ M ("!#0@ 'AL+W=O7!E&UL4$L%!@ ) - D /@( -\3 $! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_080322.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_080322.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "inline": { "local": [ "f8k_080322.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_080322.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_080322.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001171843-22-005343-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-22-005343-xbrl.zip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end